Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients;Rückgang nicht-melanozytärer Hauttumoren nach Umstellung der Immunsuppression auf mTOR-Inhibitoren bei organtransplantierten Patienten

JDDG - Journal of the German Society of Dermatology

Volumn 12, Issue 6, 2014, Pages 480-488

  Alter, Mareike ^a   Satzger, Imke ^b   Schrem, Harald ^b   Kaltenborn, Alexander ^b   Kapp, Alexander ^b   Gutzmer, Ralf ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NON MELANOMA SKIN CANCER; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; AGED; ANALOGS AND DERIVATIVES; BOWEN'S DISEASE; CARCINOMA, BASAL CELL; DRUG SUBSTITUTION; FEMALE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN NEOPLASMS;

AGED; BOWEN'S DISEASE; CARCINOMA, BASAL CELL; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SIROLIMUS; SKIN NEOPLASMS;

EID: 84901812896     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12355     Document Type: Article

References (38)

1. Krynitz B, Edgren G, Lindelof B, et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008-a Swedish population-based study. Int J Cancer 2013; 132: 1429-38.
2. Schrem H, Barg-Hock H, Strassburg CP, et al. Aftercare for patients with transplanted organs. Dtsch Arztebl Int 2009; 106: 148-56.
3. Berg D, Otley CC,. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47: 1,17; quiz 18-20.
4. Ulrich C, Schmook T, Sachse MM, et al. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 2004; 30: 622-7. (Pubitemid 38525892)
5. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S,. Skin cancer in organ transplant recipients -where do we stand today? Am J Transplant 2008; 8: 2192-8.
6. Tessari G, Naldi L, Boschiero L, et al. Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study. Arch Dermatol 2010; 146: 294-9.
7. Wisgerhof HC, Edelbroek JR, de Fijter JW, et al. Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation 2010; 89: 1231-8.
8. Euvrard S, Kanitakis J, Decullier E, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81: 1093-100.
9. Bouwes Bavinck JN, Euvrard S, Naldi L, et al. Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol 2007; 127: 1647-56. (Pubitemid 46933435)
10. Euvrard S, Kanitakis J, Claudy A,. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-91. (Pubitemid 36459475)
11. Ramsay HM, Fryer AA, Hawley CM, et al. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002; 147: 950-6. (Pubitemid 35365443)
12. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-8. (Pubitemid 28098444)
13. Thoms KM, Kuschal C, Oetjen E, et al. Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression. Exp Dermatol 2011; 20: 232-6.
14. Yarosh DB, Pena AV, Nay SL, et al. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125: 1020-5.
15. Wu X, Nguyen BC, Dziunycz P, et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010; 465: 368-72.
16. O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-4. (Pubitemid 41325100)
17. Campbell SB, Walker R, Tai SS, et al. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012; 12: 1146-56.
18. Euvrard S, Boissonnat P, Roussoulieres A, et al. Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients. Transpl Int 2010; 23: 855-7.
19. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329-39.
20. Salgo R, Gossmann J, Schofer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010; 10: 1385-93.
21. Breuninger H, Eigentler T, Bootz F, et al. Brief S2k guidelines-Cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 2013; 11 Suppl 3: 37,45, 39-47.
22. Krengel S, Satzger I, Alter M, et al. Remission of an iatrogenic Kaposi sarcoma in a patient with myasthenia gravis after switching immunosuppressive therapy to the mTOR inhibitor everolimus. Hautarzt 2012; 63: 573-6.
23. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV,. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77: 760-2. (Pubitemid 38366986)
24. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-23. (Pubitemid 40411498)
25. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-9. (Pubitemid 41552882)
26. Lebbe C, Euvrard S, Barrou B, et al. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant 2006; 6: 2164-8. (Pubitemid 44199551)
27. Chiurchiu C, Carreno CA, Schiavelli R, et al. Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies. Transplant Proc 2010; 42: 277-9.
28. Yakupoglu YK, Buell JF, Woodle S, Kahan BD,. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant Proc 2006; 38: 358-61.
29. Türk T, Witzke O, Zeier M,. KDIGO-Leitlinien zur Betreuung von Nierentransplantatempfängern-Deutsche Übersetzung. Nephrologe 2010; 5: 94-107.
30. Alberu J, Pascoe MD, Campistol JM, et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011; 92: 303-10.
31. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol 2013; 31: 1317-23.
32. Colegio OR, Hanlon A, Olasz EB, Carucci JA,. Sirolimus reduces cutaneous squamous cell carcinomas in transplantation recipients. J Clin Oncol 2013; 31: 3297-8.
33. Lonsdorf AS, Becker MR, Stockfleth E, et al. Primary and secondary prevention of skin cancer in organ transplant recipients. Hautarzt 2010; 61: 195-206.
34. Zwald FO, Brown M,. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 253, 61; quiz 262.
35. Augustine JJ, Hricik DE,. Minimization of immunosuppression in kidney transplantation. Curr Opin Nephrol Hypertens 2007; 16: 535-41. (Pubitemid 350293745)
36. Sahin GM, Sahin S, Kantarci G, Ergin H,. Proteinuria after conversion to sirolimus in renal transplant recipients. Transplant Proc 2006; 38: 3473-5. (Pubitemid 44908528)
37. van den Akker JM, Wetzels JF, Hoitsma AJ,. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 2006; 70: 1355-7. (Pubitemid 44435189)
38. Zuckermann A, Manito N, Epailly E, et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008; 27: 141-9. (Pubitemid 351221042)